Eledon Pharmaceuticals, Inc. (ELDN) has a negative trailing P/E of -5.2, meaning the company is currently unprofitable on a trailing twelve-month (TTM) basis. Trailing earnings yield is -19.29%.
Criteria proven by this page:
Overall SharesGrow Score: 60/100 with 4/7 criteria passed.
| Year | P/E (TTM) | PEG Ratio | P/B Ratio | P/S Ratio | Dividend Yield |
|---|---|---|---|---|---|
| 2016 | -0.1 | 0.00 | 0.13 | 0.00 | - |
| 2017 | -1.4 | 0.01 | 0.98 | 0.00 | - |
| 2018 | -1.0 | 0.02 | 0.99 | 0.00 | - |
| 2019 | -0.4 | 0.14 | 0.72 | 0.00 | - |
| 2020 | -1.0 | 0.02 | 0.12 | 0.00 | 0.11% |
| 2021 | -1.9 | 0.02 | 0.40 | 0.00 | - |
| 2022 | -0.4 | 0.00 | 0.39 | 0.00 | - |
| 2023 | -0.4 | 0.00 | 6.15 | 0.00 | - |
| 2024 | -5.5 | 0.00 | 1.69 | 0.00 | - |
| 2025 | -2.7 | 0.11 | 0.90 | 0.00 | - |
| Year | EPS (Diluted) | Revenue | Net Income | Net Margin |
|---|---|---|---|---|
| 2016 | $-1,785.21 | $0.00 | $-37.96M | - |
| 2017 | $-50.47 | $0.00 | $-13.12M | - |
| 2018 | $-28.11 | $0.00 | $-14.07M | - |
| 2019 | $-27.27 | $0.00 | $-17.88M | - |
| 2020 | $-15.72 | $120K | $-22.81M | -19009.2% |
| 2021 | $-2.33 | $0.00 | $-34.51M | - |
| 2022 | $-6.13 | $0.00 | $-87.5M | - |
| 2023 | $-1.64 | $0.00 | $-40.33M | - |
| 2024 | $-0.07 | $0.00 | $-35.32M | - |
| 2025 | $-0.56 | $0.00 | $-45.62M | - |
| Year | EPS (Avg) | EPS Range | Revenue (Avg) | Revenue Range | Analysts |
|---|---|---|---|---|---|
| 2026 | $-0.87 | $-1.14 – $-0.68 | $0.00 | $0.00 – $0.00 | 2 |
| 2027 | $-0.85 | $-0.85 – $-0.85 | $0.00 | $0.00 – $0.00 | 2 |
| 2028 | $-0.90 | $-1.02 – $-0.77 | $17.4M | $17.4M – $17.4M | 3 |
| 2029 | $-0.75 | $-0.75 – $-0.75 | $21.94M | $21.94M – $21.94M | 1 |
| 2030 | $-0.70 | $-0.70 – $-0.70 | $9.2M | $9.2M – $9.2M | 1 |
